
Review Finds New Alzheimer's Drugs Lack Benefit, Pose Risks
A recent comprehensive review has concluded that new Alzheimer's drugs, particularly those targeting amyloid, offer little meaningful benefit to patients and may present more risks than advantages. This finding challenges the efficacy of much-hyped treatments for the neurodegenerative disease.
Source Diversity
Source Diversity
Excellent (92/100)Sources
Report suggests 'breakthrough' Alzheimer's drugs unlikely to benefit patients
A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.
Read full article →Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.
By Pam Belluck
Read full article →Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes
Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline Drugs that have been hailed as a gamechanger for the treatment of Alzheimer’s disease make no noticeable difference to patients, according to an extensive review. The analysis of clinical trials in people with mild cognitive impairment or mild dementia found that the effects of anti-amyloid drugs on cognition and dementia severity over 18 months were “trivial”, with improvements in fu...
By Ian Sample Science editor
Read full article →Much-hyped Alzheimer’s drugs do not help patients, review finds - The Straits Times
Much-hyped Alzheimer’s drugs do not help patients, review finds The Straits Times
Read full article →Alzheimer's drugs make 'no meaningful difference'
Drugs that are said to slow the progression of Alzheimer's disease "make no meaningful difference to patients" while increasing the risk of swelling and bleeding in the brain, according to a new review.
Read full article →‘Weight-loss jabs have been hijacked by Hollywood and middle-upper-income people’ – Measuring the effects of GLP-1s on Irish society
Transformative wonder drugs or overhyped sticking plasters on a much deeper problem? GLP-1 drugs Ozempic, Wegovy, Mounjaro and Zepbound are not just so-called ‘weight-loss jabs’, but fascinating barometers of our culture, behaviour and obsession with thinness.
Read full article →Alzheimer’s drugs targeting amyloid don’t help, review finds
Despite successfully removing amyloid from the brain, the drugs don't improve cognitive function or slow its decline.
Read full article →Coverage Timeline
Related Stories

Scientists Discover Largest Ancient Scorpion, Size of a Dog
just now

'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video
just now

Hidden World Discovered 4,000 Meters Deep in the Pacific Ocean
4h ago

Scientist Awarded ₹95 Lakh Prize for Research on Zebra Finch Communication
4h ago